Casdin Partners Master Fund, L Acquires 225,000 Shares of Standard BioTools (NASDAQ:LAB) Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock in a transaction dated Monday, November 17th. The shares were bought at an average cost of $1.22 per share, for a total transaction of $274,500.00. Following the transaction, the director directly owned 62,975,000 shares of the company’s stock, valued at approximately $76,829,500. The trade was a 0.36% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Friday, November 14th, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.24 per share, with a total value of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.20 per share, for a total transaction of $540,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L acquired 375,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.19 per share, for a total transaction of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.20 per share, with a total value of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.17 per share, with a total value of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.12 per share, for a total transaction of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.29 per share, for a total transaction of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.27 per share, with a total value of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L acquired 125,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.26 per share, with a total value of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.24 per share, for a total transaction of $248,000.00.

Standard BioTools Stock Up 2.5%

Shares of NASDAQ LAB opened at $1.24 on Wednesday. The firm’s 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.23. Standard BioTools Inc. has a 52-week low of $0.92 and a 52-week high of $2.25. The stock has a market capitalization of $476.86 million, a P/E ratio of -3.88 and a beta of 1.25.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas acquired a new stake in Standard BioTools in the first quarter worth about $35,000. Vanguard Group Inc. lifted its stake in shares of Standard BioTools by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 17,225,250 shares of the company’s stock worth $18,603,000 after acquiring an additional 69,104 shares during the period. XTX Topco Ltd bought a new position in shares of Standard BioTools in the first quarter valued at approximately $171,000. Pacific Capital Partners Ltd bought a new position in shares of Standard BioTools in the first quarter valued at approximately $1,701,000. Finally, Rhumbline Advisers raised its holdings in Standard BioTools by 11.4% during the first quarter. Rhumbline Advisers now owns 412,761 shares of the company’s stock worth $446,000 after purchasing an additional 42,247 shares in the last quarter. Institutional investors and hedge funds own 53.74% of the company’s stock.

Analyst Upgrades and Downgrades

LAB has been the topic of several recent research reports. Wall Street Zen downgraded Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. TD Cowen dropped their target price on Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Standard BioTools in a report on Wednesday, October 8th. Finally, Cowen lowered shares of Standard BioTools from a “buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.